title: Cost comparison of ranibizumab and bevacizumab.
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Jackson
authors.forename: Lucy
authors.initials: L
authors.lastname: Kirkpatrick
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D003365:Costs and Cost Analysis; D006801:Humans; D000069579:Ranibizumab; D006113:United Kingdom; D057135:Wet Macular Degeneration / Q000188:drug therapy / Q000191:economics*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab